On March 22, 2024, the Food and Drug Administration (FDA) released an
emergency use authorization for the PEMGARDA (pemivibart) investigational monoclonal antibody product for pre-exposure prophylaxis of COVID-19 in certain adults and adolescents.
Providers must now use two new HCPCS codes, effective March 22, 2024:
- Product code Q0224
- Administration code M0224
Providers can visit
COVID-19 Monoclonal Antibodies for more information and get the most current
list of billing codes, including short descriptors, payment allowances, and effective and termination dates. Users may need to refresh their web browser if they recently visited the webpage.